These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 30862182)

  • 41. Demonstrating that Real World Evidence Is Fit-For-Purpose to Support Labeling: Parallels to Patient Reported Outcomes in the Pursuit of Labeling Claims.
    Girman CJ; Ritchey ME; McNeill AM; Sundell KA; Meyer RJ
    Ther Innov Regul Sci; 2021 May; 55(3):561-567. PubMed ID: 33507517
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Statistical Roadmap for Journey from Real-World Data to Real-World Evidence.
    Fang Y; Wang H; He W
    Ther Innov Regul Sci; 2020 Jul; 54(4):749-757. PubMed ID: 32557297
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Today's FDA.
    Slater EE
    N Engl J Med; 2005 Jan; 352(3):293-7. PubMed ID: 15659733
    [No Abstract]   [Full Text] [Related]  

  • 44. Clinical and regulatory features of drugs not initially approved by the FDA.
    Wang B; Avorn J; Kesselheim AS
    Clin Pharmacol Ther; 2013 Dec; 94(6):670-7. PubMed ID: 23963252
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Translational hurdles with cannabis medicines.
    Graham M; Lucas CJ; Schneider J; Martin JH; Hall W
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1325-1330. PubMed ID: 32281186
    [TBL] [Abstract][Full Text] [Related]  

  • 46. How drugs are developed and approved by the FDA: current process and future directions.
    Ciociola AA; Cohen LB; Kulkarni P;
    Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis.
    Wallach JD; Luxkaranayagam AT; Dhruva SS; Miller JE; Ross JS
    BMC Med; 2019 Jun; 17(1):117. PubMed ID: 31203816
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs.
    Ladanie A; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    Trials; 2018 Sep; 19(1):505. PubMed ID: 30231912
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review.
    Beaver JA; Howie LJ; Pelosof L; Kim T; Liu J; Goldberg KB; Sridhara R; Blumenthal GM; Farrell AT; Keegan P; Pazdur R; Kluetz PG
    JAMA Oncol; 2018 Jun; 4(6):849-856. PubMed ID: 29494733
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unapproved drugs in the United States and the Food and Drug Administration.
    Nasr A; Lauterio TJ; Davis MW
    Adv Ther; 2011 Oct; 28(10):842-56. PubMed ID: 21894470
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of Federal Regulatory Changes on Clinical Pharmacology and Drug Development: the Common Rule and the 21st Century Cures Act.
    Burris JF; Puglisi JT
    J Clin Pharmacol; 2018 Mar; 58(3):281-285. PubMed ID: 28981164
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of Real-world Data for New Drug Applications and Line Extensions.
    Bolislis WR; Fay M; Kühler TC
    Clin Ther; 2020 May; 42(5):926-938. PubMed ID: 32340916
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    de la Torre BG; Albericio F
    Molecules; 2020 Feb; 25(3):. PubMed ID: 32050446
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study.
    Wallach JD; Ciani O; Pease AM; Gonsalves GS; Krumholz HM; Taylor RS; Ross JS
    BMC Med; 2018 Mar; 16(1):45. PubMed ID: 29562926
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FDA restructures new product review centers.
    Bouchie A
    Nat Biotechnol; 2002 Oct; 20(10):960. PubMed ID: 12355100
    [No Abstract]   [Full Text] [Related]  

  • 58. New office and new leader aim to streamline FDA cancer drug review process.
    Twombly R
    J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
    [No Abstract]   [Full Text] [Related]  

  • 59. Representation of Women and Minorities in Clinical Trials for New Molecular Entities and Original Therapeutic Biologics Approved by FDA CDER from 2013 to 2015.
    Chen A; Wright H; Itana H; Elahi M; Igun A; Soon G; Pariser AR; Fadiran EO
    J Womens Health (Larchmt); 2018 Apr; 27(4):418-429. PubMed ID: 29048983
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An FDA Commissioner for the 21st Century.
    Chandra A; Sachs RE
    N Engl J Med; 2017 Apr; 376(15):e31. PubMed ID: 28402241
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.